Ke Zhang

US Patent:

7555098, Jun 30, 2009

Filed:

Jun 25, 2007

Appl. No.:

11/768096

Inventors:

Ke Zhang - Bolingbrook IL, US
Gerold Rosenbaum - Lemont IL, US

Assignee:

HD Technologies Inc. - Burr Ridge IL

International Classification:

G21K 1/06

US Classification:

378 85, 378 84

Abstract:

A detector apparatus is disclosed that includes a housing and a multilayer disposed within the housing. The multilayer defining a leading edge and a trailing edge and is adapted to interact with a plurality of high-energy photons, impingent from the leading edge, to permit passage of photons of at least one selected energy. The multilayer is secured to a first securement adjacent to the leading edge. The multilayer is secured to a second securement bracket adjacent to the trailing edge. At least one detector is disposed adjacent to the trailing edge of the multilayer to detect the impingent high-energy photons. An adjustment mechanism operatively connects to the second securement bracket to adjust the position of the second securement bracket, thereby altering an angular position of the multilayer.

US Patent:

8498820, Jul 30, 2013

Filed:

Oct 28, 2009

Appl. No.:

12/607079

Inventors:

Dimitri Semizarov - Chicago IL, US
Xin Lu - Libertyville IL, US
Ke Zhang - Grand Forks ND, US
Rick R. Lesniewski - Collegeville PA, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

G01N 33/48
G01N 33/50
G01N 31/00
G06G 7/48
G06F 19/00

US Classification:

702 19, 702 22, 703 3

Abstract:

The invention is directed to methods and kits that allow for classification of non-small cell lung carcinoma tumors and cell lines according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.

US Patent:

8498821, Jul 30, 2013

Filed:

Oct 28, 2009

Appl. No.:

12/607080

Inventors:

Dimitri Semizarov - Chicago IL, US
Xin Lu - Libertyville IL, US
Ke Zhang - Glenview IL, US
Rick R. Lesniewski - Collegeville PA, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

G01N 33/48
G01N 33/50
G01N 31/00
G06G 7/48
G06F 19/00

US Classification:

702 19, 702 22, 703 3

Abstract:

The invention is directed to methods and kits that allow for classification of malignant melanoma cells according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.

US Patent:

8498822, Jul 30, 2013

Filed:

Oct 28, 2009

Appl. No.:

12/607082

Inventors:

Dimitri Semizarov - Chicago IL, US
Xin Lu - Libertyville IL, US
Ke Zhang - Grand Forks ND, US
Rick R. Lesniewski - Collegeville PA, US

Assignee:

AbbVie Inc. - North Chicago IL

International Classification:

G01N 33/48
G01N 33/50
G01N 31/00
G06G 7/48
G06F 19/00

US Classification:

702 19, 702 22, 703 3

Abstract:

The invention is directed to methods and kits that allow for classification of colorectal cancer cells according to genomic profiles, and methods of diagnosing, predicting clinical outcomes, and stratifying patient populations for clinical testing and treatment using the same.

US Patent:

20100004306, Jan 7, 2010

Filed:

Jun 17, 2009

Appl. No.:

12/486671

Inventors:

Evelyn Mary McKeegan - Lake Forest IL, US
Saul A. Datwyler - Evanston IL, US
David J. Hawksworth - Lake Villa IL, US
Don M. Laird - Mundelein IL, US
Dominick L. Pucci - Libertyville IL, US
David C. Sogin - Highland Park IL, US
Joan D. Tyner - Beach Park IL, US
Robert N. Ziemann - Lindenhurst IL, US
Peter James Ansell - Grayslake IL, US
Ke K. Zhang - Glenview IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

A61K 31/416
G01N 33/566
A61P 35/00

US Classification:

514406, 436501

Abstract:

The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit from treatment with a drug, and the response of a subject receiving treatment (e.g., such as for cancer) by monitoring biomarkers of angiogenesis. In particular, the disclosure relates to PlGF-1 companion diagnostic methods and products.

US Patent:

20100144554, Jun 10, 2010

Filed:

Oct 28, 2009

Appl. No.:

12/607077

Inventors:

Dimitri Semizarov - Chicago IL, US
Xin Lu - Libertyville IL, US
Ke Zhang - Grand Forks ND, US
Rick R. Lesniewski - Collegeville PA, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

C40B 50/02
G06F 15/18
G05B 13/00

US Classification:

506 24, 706 13

Abstract:

The present invention relates to algorithms for use in defining genomic subgroups of tumors and cancer cell lines. The present invention also relates to methods for assembling panels of tumors and cancer cell lines according to genomic subgroups for use in testing the efficacy of one or more pharmaceutical compounds in the treatment of subjects suffering from at least one cancer.

US Patent:

20110105341, May 5, 2011

Filed:

Oct 25, 2010

Appl. No.:

12/910891

Inventors:

Dimitri Semizarov - Chicago IL, US
Xin Lu - Libertyville IL, US
Ke Zhang - Grand Forks ND, US
Rick R. Lesniewski - Collegeville PA, US
John S. Coon - Oak Park IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

C40B 30/00
C12Q 1/68

US Classification:

506 7, 435 6

Abstract:

The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci.

US Patent:

20110130295, Jun 2, 2011

Filed:

Oct 25, 2010

Appl. No.:

12/910892

Inventors:

Dimitri Semizarov - Chicago IL, US
Xin Lu - Libertyville IL, US
Ke Zhang - Grand Forks ND, US
Rick R. Lesniewski - Collegeville PA, US
John S. Coon - Oak Park IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

C40B 30/00
C12Q 1/68
C40B 40/06

US Classification:

506 7, 435 614, 435 613, 435 612, 435 611, 506 16

Abstract:

Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus.